| Study Period | 2019 - 2032 |
| Market Size in 2024 | USD 17.1 Billion |
| Market Size in 2025 | USD 18.8 Billion |
| Market Size by 2032 | USD 39.0 Billion |
| Projected CAGR | 11% |
| Largest Region | North America |
| Fastest Growing Region | APAC |
| Market Structure | Fragmented |
Explore the market potential with our data-driven report
The biologics CDMO market size was USD 17.1 billion in 2024, which is predicted to reach USD 39.0 billion by 2032, growing at a CAGR of 11.0% during 2025–2032.
This is due to the surging incidence of chronic diseases, rising outsourcing of R&D activities, companies involved in partnerships with biologics CDMOs to introduce novel products, and the growing geriatric population.
Large pharma firms are motivated to eliminate the risk of R&D efforts and upsurge the speed to market their drugs that are life changing, while continuously decreasing the cost of manufacturing and development. The increasing number of biotech and specialty firms are moving towards service providers to avoid the high-fixed cost of in-house development, manufacturing, and expertise required to get their molecules through clinical development. The complexity of new molecular entities (NMEs) development is growing, which in turn, is creating a demand for niche competencies and capabilities which pharmaceutical firms prefer to access externally rather than incorporate in-house.
In addition, high internal fixed cost bases associated with internal capabilities limit their ability to scale up and down based on the size and nature of their pipeline and ever-changing requirements. To pharmaceutical companies, CDMOs offer this flexibility and agility to spend a large portion of their profits and capital on R&D to create better drugs at lower costs, so the strategic use of external CDMO partners grants companies a substantial competitive advantage. Companies that engage CDMOs early in the R&D process are involved in the development of intellectual property (IP), the filing of patents for customers, and the assistance of customers in protecting their IP.
Moreover, pharmaceutical companies are consolidating their supplier base and prefer to work with CDMOs that provide services such as drug substance and drug product development as well as manufacturing. To meet this market demand, CDMOs are expanding their capabilities across all stages of development and commercialization in order to eliminate the need for technology transfer and serve customers end-to-end. Thus, the shift in preference toward CDMOs is another major market trend.
During the pandemic, the heightened need for vaccines and therapeutic antibodies positively affected the market. Furthermore, the pandemic revealed supply chain flaws and the world’s reliance on emerging markets, such as China and India, for APIs and generics. These factors have impelled countries to boost domestic manufacturing, to meet the supply, which CDMOs can benefit from.
The drug substance category held the larger share in the biologics CDMO market in 2024, of approximately 80%. This dominance reflects the critical importance and complexity of upstream bioprocessing, which encompasses cell line development, process optimization, and bulk drug substance manufacturing. Drug substance production represents the most technically challenging and capital-intensive aspect of biologics manufacturing, requiring sophisticated bioreactor systems, extensive process development expertise, and rigorous quality control measures. The category benefits from the increasing number of biologics entering clinical development, as every biologic drug requires optimized cell culture processes and scalable production methods that CDMOs are uniquely equipped to provide.
The drug product category is experiencing the faster growth rate, during 2025–2032, driven by the increasing complexity of biologic formulations and the growing demand for differentiated drug delivery systems. This category encompasses fill-finish operations, lyophilization, and specialized packaging requirements for biologics, which demand stringent aseptic processing capabilities and advanced containment systems. The trend toward patient-centric drug delivery formats, including prefilled syringes, autoinjectors, and novel delivery devices, is creating additional demand for specialized drug product services. CDMOs are investing heavily in state-of-the-art filling lines, isolator technology, and automated inspection systems to meet the evolving requirements of biologic drug products.
The product types analyzed include:
The mammalian category dominated the biologics CDMO market in 2024, commanding approximately 65% share, reflecting its essential role in producing complex therapeutic proteins that require post-translational modifications for biological activity. Mammalian cell systems, particularly Chinese Hamster Ovary (CHO) cells, have become the industry standard for manufacturing monoclonal antibodies, fusion proteins, and other complex biologics due to their ability to perform human-like glycosylation patterns critical for drug efficacy and safety. The category benefits from decades of process optimization, established regulatory precedents, and proven scalability from laboratory to commercial manufacturing scales.
The viral vector & other modalities category is witnessing the highest CAGR, during the forecast period, driven by the revolutionary emergence of cell and gene therapies. This category encompasses the production of adeno-associated virus (AAV) vectors, lentiviral vectors, and other delivery systems essential for advanced therapy medicinal products (ATMPs). The rapid advancement in gene therapy development, with multiple products receiving regulatory approvals and hundreds in clinical trials, is creating unprecedented demand for specialized viral vector manufacturing capabilities. CDMOs are establishing dedicated facilities and developing proprietary platforms to address the unique challenges of viral vector production, including scalability limitations, complex purification requirements, and stringent safety considerations.
The segment includes:
The commercial manufacturing category held the larger biologics CDMO market share in 2024, of 75%, driven by the increasing number of approved biologics requiring large-scale production capabilities. Commercial manufacturing services encompass the complex ecosystem of activities required to produce biologics at scale while maintaining consistent quality and regulatory compliance across global markets. This category benefits from long-term contracts typically spanning 5–10 years, providing stable revenue streams for CDMOs while ensuring supply security for pharmaceutical companies. The increasing adoption of biosimilars, which require cost-effective large-scale manufacturing to compete with originator biologics, further strengthens demand for commercial manufacturing services.
The clinical manufacturing category is experiencing robust growth, during 2025–2032, fueled by the expanding pipeline of biologics in development and the increasing complexity of clinical trial designs. Clinical manufacturing services are essential for producing investigational biologics for Phase I through Phase III trials, requiring flexibility to accommodate process changes while maintaining regulatory compliance. The trend toward personalized medicine and smaller patient populations for orphan drugs is driving demand for flexible, small-scale manufacturing capabilities that can efficiently produce clinical supplies for targeted therapies. CDMOs are investing in modular production systems and platform technologies that enable rapid process development and seamless scale-up from clinical to commercial manufacturing.
The segment includes:
Drive strategic growth with comprehensive market analysis
North America held the largest share in the biologics CDMO market in 2024, of 40%. This is primarily attributed to the presence of a robust biopharmaceutical industry, with the U.S. hosting the headquarters of major pharmaceutical companies and numerous innovative biotech firms that drive demand for CDMO services. The region benefits from a well-established regulatory framework under the FDA that provides clear pathways for biologics approval, encouraging investment in biomanufacturing capabilities and fostering innovation in bioprocessing technologies.
The market growth in North America is further accelerated by substantial investments in biomanufacturing infrastructure, with both government initiatives and private sector funding supporting capacity expansion. According to a White House report released in November 2024, the President's commitment to growing the bioeconomy has spurred $46 billion in public and private sector biomanufacturing investments for projects across the U.S. since the inauguration of the Biden–Harris Administration.
Asia-Pacific is expected to be the fastest-growing regional market, with a projected CAGR of approx. 11.5% during 2025–2032, driven by rapidly expanding biopharmaceutical sectors in China, India, and South Korea. The region's growth is fueled by increasing investments in biomanufacturing infrastructure, favorable government policies supporting biotechnology development, and the growing expertise in biosimilar development and manufacturing. China, in particular, has emerged as a major force in the global biologics CDMO market, with companies establishing world-class facilities that meet international quality standards while offering cost-competitive services.
The region benefits from a large and growing patient population, rising healthcare expenditure, and improving regulatory frameworks that align with international standards.
The availability of skilled scientific talent at competitive costs, combined with government initiatives to promote pharmaceutical manufacturing, positions Asia-Pacific as an increasingly attractive destination for biologics manufacturing outsourcing. Additionally, the region's growing domestic demand for biologics, driven by increasing disease prevalence and improving healthcare access, creates opportunities for CDMOs to serve both local and global markets.
The regions and countries analyzed in this report are:
The biologics CDMO market is primarily fragmented, consisting of a large number of small and mid-sized contract development and manufacturing organizations that provide specialized services across different stages of biologics development and production. This fragmentation allows companies to cater to diverse client needs, including large pharmaceutical firms and emerging biotechnology companies, offering flexibility and niche expertise. However, the market is also witnessing a gradual trend of consolidation, as larger CDMOs acquire smaller players to expand their service portfolios, integrate end-to-end capabilities, and enhance their global presence. Despite this consolidation activity, the market remains largely fragmented due to the continued presence of numerous specialized players serving various segments of the biologics industry.
Want a report tailored exactly to your business need?
Request CustomizationLeading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws
Customize the Report to Align with Your Business Objectives
Request the Free Sample Pages